Acutaas Chemicals vs Natco Pharma: Share Price, Valuation and Results Compared

Acutaas Chemicals Ltd (NSE: ACUTAAS) and Natco Pharma Ltd (NSE: NATCOPHARM) are both listed in the Medicinal Chemicals and Botanical Products industry. Acutaas Chemicals has a market capitalisation of ₹32,068 Cr and Natco Pharma ₹15,869 Cr, as of 16 Nov 2026. Their P/E ratios are 92.2 and 10.2 respectively. Return on equity is 23.52% for Acutaas Chemicals and 16.85% for Natco Pharma. Over one year, Acutaas Chemicals's share price is up 128.8% and Natco Pharma's is up 1.0%.

Acutaas Chemicals vs Natco Pharma — Key Figures

MetricAcutaas ChemicalsNatco Pharma
NSE SymbolACUTAASNATCOPHARM
BSE Code543349524816
Share Price₹4,055.00₹808.00
Market Cap₹32,068 Cr₹15,869 Cr
P/E Ratio92.210.2
Return on Equity23.52%16.85%
Return on Assets15.74%7.98%
Dividend Yield0.06%0.56%
Beta (1Y)0.310.17
1-Year Price Change+128.8%+1.0%
3-Month Price Change+29.8%-14.8%
52-Week Range₹1,602.50 – ₹4,130.00₹773.60 – ₹1,226.80
Latest QuarterQ2 FY27Q2 FY27
Quarterly Revenue₹437 Cr₹967 Cr
Quarterly Net Profit₹123 Cr₹203 Cr
Net Margin28.2%20.9%
EPS (Basic, Quarter)₹15.29₹11.31
Results Basisconsolidatedconsolidated
HeadquartersSurat, GujaratHyderabad, Telangana

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

Acutaas Chemicals Ltd

Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrol…

Natco Pharma Ltd

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and in…

Frequently Asked Questions

Which is larger by market cap, Acutaas Chemicals or Natco Pharma?

Acutaas Chemicals has a market capitalisation of ₹32,068 Cr, against ₹15,869 Cr for Natco Pharma as of 16 Nov 2026, about 2.0 times the size by market cap.

What is the P/E ratio of Acutaas Chemicals and Natco Pharma?

Acutaas Chemicals has a P/E of 92.2 and Natco Pharma a P/E of 10.2 as of 16 Nov 2026.

What is the return on equity of Acutaas Chemicals and Natco Pharma?

Acutaas Chemicals has a return on equity of 23.52% and Natco Pharma 16.85%.

How have Acutaas Chemicals and Natco Pharma shares moved over one year?

Acutaas Chemicals's share price is up 128.8% over one year and Natco Pharma's is up 1.0%.

What were the latest quarterly results of Acutaas Chemicals and Natco Pharma?

Acutaas Chemicals reported revenue of ₹437 Cr and net profit of ₹123 Cr for Q2 FY27. Natco Pharma reported revenue of ₹967 Cr and net profit of ₹203 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are Acutaas Chemicals and Natco Pharma in?

Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.

Is this comparison a recommendation to buy or sell Acutaas Chemicals or Natco Pharma?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.